PharmaLogic Holdings Corp., a contract development and manufacturing organization (CDMO) specializing in radiopharmaceuticals, will acquire a majority stake in Agilera Pharma, a contract development and manufacturing organization, from the Institute for Energy Technology (IFE) in Norway.
Closing of the transaction is subject to customary conditions, including regulatory approvals, license transfers and certain third-party consents. The acquisition is expected to close in June of 2025.
Under the terms of the agreement, Agilera will complement PharmaLogic’s existing manufacturing platform for therapeutics.
Led by Etienne Montagut, President, and Erik Flatmark, CEO, Agilera has been a partner for major pharmaceutical companies for more than a decade, manufacturing commercial radiopharmaceutical therapies across the United States, Europe, and Asia. With more than 600,000 commercial therapeutic doses delivered to more than 40 countries, Agilera stands as a leader in the radiopharmaceutical CDMO space, further advancing PharmaLogic’s commitment to innovation and excellence in the industry.
PharmaLogic is committed to investing in the expansion of Agilera’s CDMO capabilities, strengthening its infrastructure, and scaling its manufacturing footprint to meet rising global demand for radiopharmaceutical therapeutics. This acquisition establishes PharmaLogic as the only CDMO with a global presence actively producing and distributing one of the main commercially-approved radiopharmaceutical therapies for major pharmaceutical companies.
PharmaLogic is a contract development and manufacturing organization specializing in novel diagnostic imaging and therapeutic radiopharmaceuticals for the treatment of cancers and other malignancies. In addition to an established and reliable network of radiopharmacies, PharmaLogic has decades of expertise in drug development from discovery, through manufacturing and commercialization.
FinSMEs
09/04/2025